These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27479566)

  • 1. STAMPEDE trial and patients with non-metastatic prostate cancer - Authors' reply.
    James ND; Sydes MR; Clarke NW; Mason MD; Parmar MK
    Lancet; 2016 Jul; 388(10041):235-6. PubMed ID: 27479566
    [No Abstract]   [Full Text] [Related]  

  • 2. STAMPEDE trial and patients with non-metastatic prostate cancer.
    Gandaglia G; Fossati N; Suardi N; Montorsi F; Briganti A
    Lancet; 2016 Jul; 388(10041):234-5. PubMed ID: 27479564
    [No Abstract]   [Full Text] [Related]  

  • 3. Defining new standards of care for men with prostate cancer.
    Scher HI
    Lancet; 2016 Mar; 387(10024):1135-7. PubMed ID: 27025318
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate cancer: Changing standard of care in hormone-sensitive disease.
    Thoma C
    Nat Rev Urol; 2016 Feb; 13(2):61. PubMed ID: 26787390
    [No Abstract]   [Full Text] [Related]  

  • 5. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
    James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Spears MR; Ritchie AW; Parker CC; Russell JM; Attard G; de Bono J; Cross W; Jones RJ; Thalmann G; Amos C; Matheson D; Millman R; Alzouebi M; Beesley S; Birtle AJ; Brock S; Cathomas R; Chakraborti P; Chowdhury S; Cook A; Elliott T; Gale J; Gibbs S; Graham JD; Hetherington J; Hughes R; Laing R; McKinna F; McLaren DB; O'Sullivan JM; Parikh O; Peedell C; Protheroe A; Robinson AJ; Srihari N; Srinivasan R; Staffurth J; Sundar S; Tolan S; Tsang D; Wagstaff J; Parmar MK;
    Lancet; 2016 Mar; 387(10024):1163-77. PubMed ID: 26719232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabazitaxel for castration-resistant prostate cancer.
    Froehner M; Wirth MP
    Lancet; 2011 Jan; 377(9760):121-2; author reply 122-3. PubMed ID: 21215875
    [No Abstract]   [Full Text] [Related]  

  • 7. Cabazitaxel for castration-resistant prostate cancer.
    Shigeta K; Miura Y; Naito Y; Takano T
    Lancet; 2011 Jan; 377(9760):121; author reply 122-3. PubMed ID: 21215876
    [No Abstract]   [Full Text] [Related]  

  • 8. Metastatic prostate cancer in 2015: The new and the old that is new again.
    Graff JN; Beer TM
    Nat Rev Clin Oncol; 2016 Feb; 13(2):73-4. PubMed ID: 26718107
    [No Abstract]   [Full Text] [Related]  

  • 9. [Optimal treatment for elderly high-risk prostate cancer patients].
    Soga N; Sugimura Y
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):387-92. PubMed ID: 17353629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates in prostate cancer: where are we and where should we go?
    Saad F
    J Natl Cancer Inst; 2003 Sep; 95(17):1262-3. PubMed ID: 12953073
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
    Kamba T; Kamoto T; Maruo S; Kikuchi T; Shimizu Y; Namiki S; Fujimoto K; Kawanishi H; Sato F; Narita S; Satoh T; Saito H; Sugimoto M; Teishima J; Masumori N; Egawa S; Sakai H; Okada Y; Terachi T; Ogawa O;
    Int J Clin Oncol; 2017 Feb; 22(1):166-173. PubMed ID: 27614621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
    James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Anderson J; Popert RJ; Sanders K; Morgan RC; Stansfeld J; Dwyer J; Masters J; Parmar MK
    BJU Int; 2009 Feb; 103(4):464-9. PubMed ID: 18990168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for metastatic castrate-sensitive prostate cancer.
    Miller RE; Sweeney CJ
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):139-44. PubMed ID: 26976365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?
    Ural AU; Avcu F
    Acta Oncol; 2006; 45(4):491-2. PubMed ID: 16760189
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
    Yuasa T
    Int J Urol; 2009 Sep; 16(9):731-2. PubMed ID: 19769657
    [No Abstract]   [Full Text] [Related]  

  • 18. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.
    Singer EA; Srinivasan R
    Urol Oncol; 2012; 30(4 Suppl):S15-9. PubMed ID: 22014836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial.
    Uemura H; Yanagisawa M; Ikeda I; Fujinami K; Iwasaki A; Noguchi S; Noguchi K; Kubota Y;
    Int J Clin Oncol; 2013 Jun; 18(3):472-7. PubMed ID: 22491982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.